Nurse Practitioner Program year 2022 Reported 2021–2022 Source: CMS Open Payments, 2026 publication

Jessica Saunders

Nurse Practitioner, Family Roanoke, VA Nurse Practitioner

NPI 1881148732 CMS profile 10792384

2602 Franklin Rd Sw, Roanoke, VA 24014

Open in the dashboard

General payments

$11,825

32 records reported · program years 2021–2022

Research payments

$0

Paid to them · None reported · program years 2021–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Jessica Saunders of Roanoke, VA is reported in the CMS Open Payments database as having received $11,825 across 32 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $1,577 8
2021 General $10,248 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Saunders
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jessica Saunders were reported at $0. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jessica Saunders Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $10,248 $124 $35–$379 $132
2022 $1,577 $141 $44–$430 $149
2023 $0 $154 $49–$476 $160
2024 $0 $165 $51–$504 $164
2025 $0 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2022
  1. Mallinckrodt Hospital Products Inc. $11,433 18 payments
  2. Relypsa, Inc. $238 5 payments
  3. Akebia Therapeutics Inc $67 4 payments
  4. Abbott Laboratories $55 3 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $21 1 payment
  6. AstraZeneca Pharmaceuticals LP $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,720 8 payments
  2. Travel and Lodging $1,422 6 payments
  3. Food and Beverage $659 16 payments
  4. Education $24 2 payments
Products named General payments · program years 2021–2022
  1. ACTHAR $11,433 18 payments
  2. Veltassa $117 2 payments
  3. Auryxia $67 4 payments
  4. FreeStyle Libre $55 3 payments
  5. Kerendia $21 1 payment
  6. Korsuva $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 91 drugs

Part D claims

3,487

Median for Nurse Practitioner: 389

Drug cost

$153,313

Median for Nurse Practitioner: $21,885

Branded share of claims

16%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 97 $38,175
Januvia Sitagliptin Phosphate Brand 37 $13,756
Farxiga Dapagliflozin Propanediol Brand 18 $10,436
Xarelto Rivaroxaban Brand 14 $8,046
Gabapentin Generic 350 $7,814
Jardiance Empagliflozin Brand 11 $6,718
Lacosamide Generic 21 $5,961
Lantus Insulin Glargine,hum.Rec.Anlog Brand 23 $2,947
Oxycodone Hcl Generic 112 $2,841
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 75 $2,784

The 10 drugs with the highest cost, of 91 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$83,803

Medicare's payments for the services billed

Medicare patients

247

Average age 80

Services billed

1,327

158 women, 89 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 74%
Alzheimer's or dementia 63%
Arthritis 55%
Heart failure 46%
Diabetes 44%
Chronic kidney disease 40%
Ischemic heart disease 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

32 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record